Definition and research guide
This page combines a MeSH definition, publication statistics and selected research abstracts. It is a starting point for reading the literature, not a medical textbook or a systematic evidence review.
Content available: 4 complete abstracts (921 words), 10 references. Full article text is not stored or reproduced here; follow the PMID, DOI or PMC links to read the original sources and their access terms.
Definition
An antibiotic produced by Streptomyces spectabilis. It is active against gram-negative bacteria and used for the treatment of gonorrhea.
Definition: NLM Medical Subject Headings (MeSH) scope note (Public domain (U.S. National Library of Medicine); attribution requested). View the MeSH record.
Also known as: Actinospectacin; Spectam; Trobicin; Spectinomycin Dihydrochloride, Anhydrous; Prospec; Spectinomycin Hydrochloride; Adspec; Ferkel Spectam.
Where it fits in the MeSH classification
- Broader topics
- Dioxanes; Heterocyclic Compounds, 3-Ring; Aminoglycosides
Related concepts
Research landscape
PubMed indexes 1,307 records tagged with the MeSH heading “Spectinomycin” (counts retrieved 2026-10-31). 72 of them (5.5%) were published from 2020 onward, and the busiest period so far is through 1999 with 934 records.
Reviews account for 51 records (3.9%) and meta-analyses for 1. Randomized controlled trials number 44 (3.4%) as a share of all records on the topic.
Show the data
| Period | Records |
|---|---|
| through 1999 | 934 |
| 2000-2009 | 153 |
| 2010-2019 | 148 |
| 2020 onward | 72 |
Publication-type chart data
| Type | Records | Share |
|---|---|---|
| Reviews | 51 | 3.9% |
| Meta-analyses | 1 | 0.1% |
| Randomized controlled trials | 44 | 3.4% |
Method: PubMed query "Spectinomycin"[MeSH Terms] with publication-type and date filters, retrieved 2026-10-31.
Reading the evidence in drugs and chemicals
Studies of a chemical or drug can answer very different questions: what it is and how it behaves in cells and animals, how the body handles it, and whether it changes outcomes in people. Laboratory and animal findings often do not carry over to patients, and observational studies of exposures are confounded by who uses a substance and why. Nothing on this page is a recommendation to use, avoid, start or stop any substance or medicine; talk to a qualified clinician or pharmacist about your own situation. Check the dose, the species, the comparison group and whether a patient-relevant outcome was measured.
Evidence from open-access studies
These open-access studies come from PubMed’s best-match results for this heading (papers whose main topic it is), ranked here by citation count, with one recent addition. Each abstract is reproduced in full under its recorded open licence so that you can read the authors’ own words. They illustrate the literature; they are not a systematic summary of it. Citation counts measure attention, not reliability or clinical benefit.
Spectinamides are effective partner agents for the treatment of tuberculosis in multiple mouse infection models [1]
Abstract reading summary — source excerpts
- Opening excerpt
- ObjectivesNew drug regimens employing combinations of existing and experimental antimicrobial agents are needed to shorten treatment of tuberculosis (TB) in humans.
- Closing excerpt
- These data support further development of the spectinamides as combination partners with existing and experimental anti-TB agents.
- Interpretation limits
- Verbatim excerpts from the authors’ abstract; the closing excerpt may describe a finding, limitation or recommendation. Design, population, effect size and uncertainty have not been independently extracted or appraised. Read the complete abstract and linked paper before interpreting the findings.
Read complete abstract (252 words)
ObjectivesNew drug regimens employing combinations of existing and experimental antimicrobial agents are needed to shorten treatment of tuberculosis (TB) in humans. The spectinamides are narrow-spectrum semisynthetic analogues of spectinomycin, modified to avoid intrinsic efflux by Mycobacterium tuberculosis . Spectinamides, including lead 1599, have been previously shown to exhibit a promising therapeutic profile in mice as single agents. Here we explore the in vivo activity of lead spectinamides when combined with other agents.MethodsThe efficacy of 1599 or 1810 was tested in combination in three increasingly advanced TB mouse models. Mice were infected by aerosol and allowed to establish acute or chronic infection, followed by treatment (≤4 weeks) with the spectinamides alone or in two- and three-drug combination regimens with existing and novel therapeutic agents. Bacteria were enumerated from lungs by plating for cfu.ResultsHerein we show the following: (i) 1599 exhibits additive or synergistic activity with most of the first-line agents; (ii) 1599 in combination with rifampicin and pyrazinamide or with bedaquiline and pyrazinamide promotes significantly improved efficacy in the high-dose aerosol model; (iii) 1599 enhances efficacy of rifampicin or pyrazinamide in chronically infected BALB/c mice; and (iv) 1599 is synergistic when administered in combination with rifampicin and pyrazinamide in the C3HeB/FeJ mouse model showing caseous necrotic pulmonary lesions.ConclusionsSpectinamides were effective partner agents for multiple anti-TB agents including bedaquiline, rifampicin and pyrazinamide. None of these in vivo synergistic interactions was predicted from in vitro MIC chequerboard assays. These data support further development of the spectinamides as combination partners with existing and experimental anti-TB agents.
Abstract reproduced from the open-access article under the recorded cc by licence; © the authors. PMID 27999020 · DOI · PMC5400088
Chlamydia trachomatis and Chlamydia muridarum spectinomycin resistant vectors and a transcriptional fluorescent reporter to monitor conversion from replicative to infectious bacteria [2]
Abstract reading summary — source excerpts
- Opening excerpt
- Chlamydia trachomatis infections are the leading cause of sexually transmitted infections of bacterial origin.
- Closing excerpt
- Altogether, the Chlamydia genetic tools described here will benefit the field, as we continue to investigate the molecular mechanisms underlying Chlamydia-host interaction and pathogenesis.
- Interpretation limits
- Verbatim excerpts from the authors’ abstract; the closing excerpt may describe a finding, limitation or recommendation. Design, population, effect size and uncertainty have not been independently extracted or appraised. Read the complete abstract and linked paper before interpreting the findings.
Read complete abstract (250 words)
Chlamydia trachomatis infections are the leading cause of sexually transmitted infections of bacterial origin. Lower genital tract infections are often asymptomatic, and therefore left untreated, leading to ascending infections that have long-term consequences on female reproductive health. Human pathology can be recapitulated in mice with the mouse adapted strain C. muridarum. Eight years into the post-genetic era, significant advances to expand the Chlamydia genetic toolbox have been made to facilitate the study of this important human pathogen. However, the need for additional tools remains, especially for C. muridarum. Here, we describe a new set of spectinomycin resistant E. coli-Chlamydia shuttle vectors, for C. trachomatis and C. muridarum. These versatile vectors allow for expression and localization studies of Chlamydia effectors, such as Inc proteins, and will be instrumental for mutant complementation studies. In addition, we have exploited the differential expression of specific Chlamydia genes during the developmental cycle to engineer an omcA::gfp fluorescent transcriptional reporter. This novel tool allows for monitoring RB to EB conversion at the bacterial level. Spatiotemporal tracking of GFP expression within individual inclusions revealed that RB to EB conversion initiates in bacteria located at the edge of the inclusion and correlates with the time post initiation of bacterial replication and inclusion size. Comparison between primary and secondary inclusions potentially suggests that the environment in which the inclusions develop influences the timing of conversion. Altogether, the Chlamydia genetic tools described here will benefit the field, as we continue to investigate the molecular mechanisms underlying Chlamydia-host interaction and pathogenesis.
Abstract reproduced from the open-access article under the recorded cc by licence; © the authors. PMID 31170215 · DOI · PMC6553856
Single-molecule correlated chemical probing reveals large-scale structural communication in the ribosome and the mechanism of the antibiotic spectinomycin in living cells [3]
Abstract reading summary — source excerpts
- Opening excerpt
- The ribosome moves between distinct structural states and is organized into multiple functional domains.
- Closing excerpt
- Single-molecule correlated chemical probing reveals trans-domain structural communication and rationalizes the profound functional effects of binding by a low-molecular-mass antibiotic to the megadalton ribosome.
- Interpretation limits
- Verbatim excerpts from the authors’ abstract; the closing excerpt may describe a finding, limitation or recommendation. Design, population, effect size and uncertainty have not been independently extracted or appraised. Read the complete abstract and linked paper before interpreting the findings.
Read complete abstract (199 words)
The ribosome moves between distinct structural states and is organized into multiple functional domains. Here, we examined hundreds of occurrences of pairwise through-space communication between nucleotides in the ribosome small subunit RNA using RNA interaction groups analyzed by mutational profiling (RING-MaP) single-molecule correlated chemical probing in bacterial cells. RING-MaP revealed four structural communities in the small subunit RNA, each distinct from the organization defined by the RNA secondary structure. The head domain contains 2 structural communities: the outer-head contains the pivot for head swiveling, and an inner-head community is structurally integrated with helix 44 and spans the entire ribosome intersubunit interface. In-cell binding by the antibiotic spectinomycin (Spc) barely perturbs its local binding pocket as revealed by the per-nucleotide chemical probing signal. In contrast, Spc binding overstabilizes long-range RNA-RNA contacts that extend 95 Å across the ribosome that connect the pivot for head swiveling with the axis of intersubunit rotation. The two major motions of the small subunit-head swiveling and intersubunit rotation-are thus coordinated via long-range RNA structural communication, which is specifically modulated by Spc. Single-molecule correlated chemical probing reveals trans-domain structural communication and rationalizes the profound functional effects of binding by a low-molecular-mass antibiotic to the megadalton ribosome.
Abstract reproduced from the open-access article under the recorded cc by licence; © the authors. PMID 31487286 · DOI · PMC6748448
Evidence for a Constrained Mutational Pathway to High-Level Spectinomycin Resistance in Neisseria: RpsE Loop 2 Mutations and Associated Growth Costs [4]
Abstract reading summary — source excerpts
- Opening excerpt
- Antimicrobial resistance in Neisseria gonorrhoeae is a global concern.
- Closing excerpt
- This constraint may help explain the rapid decline of resistant variants in the absence of drug pressure and underscores the importance of genomic surveillance.
- Interpretation limits
- Verbatim excerpts from the authors’ abstract; the closing excerpt may describe a finding, limitation or recommendation. Design, population, effect size and uncertainty have not been independently extracted or appraised. Read the complete abstract and linked paper before interpreting the findings.
Read complete abstract (220 words)
Antimicrobial resistance in Neisseria gonorrhoeae is a global concern. Spectinomycin is unusual in that resistance can emerge rapidly during localized outbreaks yet often disappears from clinical populations after drug withdrawal, suggesting an associated growth cost. To investigate evolutionary routes to spectinomycin resistance, we performed in vitro selection on two N. gonorrhoeae strains and two commensal Neisseria species. Derived cell lines were characterized by minimum inhibitory concentration (MIC) determination, whole-genome sequencing, growth-kinetics analysis, and molecular modelling of the RpsE (ribosomal protein S5) interface with the ribosome. All high-level resistant isolates (MIC > 2048 mg/L) acquired substitutions or deletions in loop 2 of RpsE. Modelling showed that these mutations perturb the conserved network of stabilizing contacts between RpsE residues Lys25 (Lys23 in E. coli numbering) and Lys28 (Lys26), as well as helix 34 nucleotides G922, A923, and C1069 of 16S rRNA, potentially altering the architecture of the spectinomycin-binding site. These mutations were associated with high-level resistance but reduced growth rates, with the resulting growth costs depending on the specific pattern of contact rearrangements. Convergent evolution towards loop 2 mutations supports the existence of a constrained mutational pathway to high-level spectinomycin resistance in the strains and species examined here. This constraint may help explain the rapid decline of resistant variants in the absence of drug pressure and underscores the importance of genomic surveillance.
Abstract reproduced from the open-access article under the recorded cc by licence; © the authors. PMID 42450237 · DOI · PMC13361928
Key reviews and meta-analyses
The most cited review-type papers among PubMed’s best-match results for this heading, listed with bibliographic details only. Follow the links for the full text and access terms.
- Research article Drugs five years later. Spectinomycin [5]
- Research article Spectinomycin [6]
- Research article New antibiotics: epicillin, minocycline and spectinomycin a summary of their antibacterial activity, pharmacokinetic properties and therapeutic efficacy [7]
- Research article Fed-batch bioproduction of spectinomycin [8]
- Research article Chemistry of spectinomycin [9]
- Research article Cefmetazole and trospectomycin in vitro susceptibility testing interpretive criteria and quality control guidelines for Neisseria gonorrheae [10]
References
- Robertson GT, Scherman MS, Bruhn DF, Liu J, Hastings C, McNeil MR, et al.. Spectinamides are effective partner agents for the treatment of tuberculosis in multiple mouse infection models. . 2017. PMID 27999020 · DOI · PMC5400088
- Cortina ME, Ende RJ, Bishop RC, Bayne C, Derré I. Chlamydia trachomatis and Chlamydia muridarum spectinomycin resistant vectors and a transcriptional fluorescent reporter to monitor conversion from replicative to infectious bacteria. . 2019. PMID 31170215 · DOI · PMC6553856
- Sengupta A, Rice GM, Weeks KM. Single-molecule correlated chemical probing reveals large-scale structural communication in the ribosome and the mechanism of the antibiotic spectinomycin in living cells. . 2019. PMID 31487286 · DOI · PMC6748448
- Kravtsov DV, Gryadunov DA, Anashkina AA, Shaskolskiy BL. Evidence for a Constrained Mutational Pathway to High-Level Spectinomycin Resistance in Neisseria: RpsE Loop 2 Mutations and Associated Growth Costs. . 2026. PMID 42450237 · DOI · PMC13361928
- McCormack WM, Finland M. Drugs five years later. Spectinomycin. Ann Intern Med. 1976. PMID 132888 · DOI
- Holloway WJ. Spectinomycin. Med Clin North Am. 1982. PMID 6460907 · DOI
- Brogden RN, Avery GS. New antibiotics: epicillin, minocycline and spectinomycin a summary of their antibacterial activity, pharmacokinetic properties and therapeutic efficacy. Drugs. 1972. PMID 4265722 · DOI
- Gomes J, Menawat AS. Fed-batch bioproduction of spectinomycin. Adv Biochem Eng Biotechnol. 1998. PMID 9435459 · DOI
- Rosenbrook W. Chemistry of spectinomycin. Jpn J Antibiot. 1979. PMID 162066
- Jones RN, Erwin ME, Washington JA, Koontz FP, Murray PR, Gerlach EH. Cefmetazole and trospectomycin in vitro susceptibility testing interpretive criteria and quality control guidelines for Neisseria gonorrheae. Diagn Microbiol Infect Dis. 1992. PMID 1424520 · DOI
About this article
- Sources
- NLM Medical Subject Headings (definition, synonyms); NCBI PubMed (counts, identifiers); Europe PMC (open-access abstracts and citation counts).
- Verification
- Every reference was resolved against PubMed on 2026-10-31; title, year and DOI matched.
- Review state
- automated source verified; no human expert review has been recorded yet.
- Version
- 1, last updated 2026-10-31.
See how EvidenceLib is built. Spotted an error? Email support@evidencehelix.com.
Evidence strength
EvidenceHelix's computed view of the study designs behind this topic: how common meta-analyses, randomized trials and reviews are, how recent the literature is, and a plain-language reading. It describes the design mix of the literature. It is not a quality appraisal of any study, and it is not medical advice.